Tuberculosis remains a stubborn paradox in global health: three decades of hard-won gains in reducing mortality are now threatened by drug resistance, funding cuts, and the lingering shadow of HIV co-infection. For the hundreds of millions of adults concerned with infectious disease risk and longevity, this landmark analysis offers the most comprehensive accounting yet of where the world stands — and how far it has to go before the WHO's 2035 elimination targets become realistic.
Drawing on the Global Burden of Disease Study 2023, researchers analyzed TB burden across 204 countries and territories from 1990 to 2023, stratifying outcomes by HIV status and drug-resistance profile. The methodology combined vital registration data, surveillance records, verbal autopsies, and minimally invasive tissue sampling, processed through the Cause of Death Ensemble (CODEm) platform and DisMod-MR 2.1 for simultaneous incidence-prevalence-mortality modeling. Disability-adjusted life-years (DALYs) were computed as a composite of years of life lost and years lived with disability. A comparative risk assessment framework quantified attributable fractions for alcohol use, smoking, and elevated fasting plasma glucose — three modifiable risk factors with meaningful TB susceptibility links. Multidrug-resistant TB (MDR-TB) was tracked as a distinct stratum, reflecting its disproportionate burden on treatment systems and mortality trajectories.
The breadth of this systematic analysis places it among the most consequential TB assessments in years. Earlier GBD iterations showed TB mortality declining roughly 36% between 1990 and the early 2020s, but MDR-TB prevalence has grown as a share of total cases, complicating that narrative. The HIV-TB co-epidemic remains concentrated in sub-Saharan Africa, where immunosuppression amplifies TB lethality dramatically. Critically, this analysis arrives just as global health funding retractions — most notably from U.S. foreign aid reductions — threaten TB surveillance infrastructure in high-burden nations. The inclusion of modifiable metabolic and behavioral risk factors broadens the conversation: rising diabetes prevalence globally may quietly expand TB vulnerability in populations previously considered lower-risk. For a health-conscious audience, the takeaway is that TB is not a static background disease but a dynamic system sensitive to both biomedical and lifestyle determinants. The WHO 2035 targets appear increasingly aspirational rather than achievable without course correction.